Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gemin X Pharmaceuticals Inc.

Division of Teva Pharmaceutical Industries Ltd.
www.geminx.com

Latest From Gemin X Pharmaceuticals Inc.

Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech

Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.

BioPharmaceutical Business Strategies

H.I.G. Capital raises $268M for new bioventures fund

H.I.G. Capital, a global private equity firm with more than $8.5 billion under management, has closed its second life sciences-focused venture fund - H.I.G. BioVentures II – at $268 million, exceeding its $250 million target. Like its first life sciences fund, HIG BioVentures, the new fund will invest in North American companies across a broad range of sectors and development stages, with a focus on pharmaceuticals, medical devices, and diagnostics.

Neurology Canada

H.I.G. BioVentures Closes Second Fund Above Target, Team Upbeat

H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.

North America

The end really is nigh for Genasense in melanoma

Genta has finally put an end to the long and troubled development of its investigational antisense therapy Genasense for melanoma. While Harold Camping is just the latest in a series of false prophets predicting the end of the world, Genasense observers who had predicted the demise of the compound since before its first phase III melanoma failure back in 2004 have now been proved right.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Gemin X Biotechnologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Teva Pharmaceutical Industries Ltd.
  • Senior Management
  • Peter Dolan, Chmn. & CEO
    Michael Dixon, CFO
    Gordon Shore, PhD, CSO
  • Contact Info
  • Gemin X Pharmaceuticals Inc.
    Phone: (514) 281-8989
    3576 Ave. du Parc
    Ste. 4310
    Montreal, H2X 2H7
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register